Form 8-K

8-K — Perspective Therapeutics, Inc.

Accession: 0001193125-26-342495

Filed: 2026-08-10

Period: 2026-08-10

CIK: 0000728387

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — catx-20260810.htm (Primary)

EX-99.1 (catx-ex99_1.htm)

EX-99.2 (catx-ex99_2.htm)

GRAPHIC (img236230851_0.jpg)

GRAPHIC (catx-ex99_2s1.jpg)

GRAPHIC (catx-ex99_2s2.jpg)

GRAPHIC (catx-ex99_2s3.jpg)

GRAPHIC (catx-ex99_2s4.jpg)

GRAPHIC (catx-ex99_2s5.jpg)

GRAPHIC (catx-ex99_2s6.jpg)

GRAPHIC (catx-ex99_2s7.jpg)

GRAPHIC (catx-ex99_2s8.jpg)

GRAPHIC (catx-ex99_2s9.jpg)

GRAPHIC (catx-ex99_2s10.jpg)

GRAPHIC (catx-ex99_2s11.jpg)

GRAPHIC (catx-ex99_2s12.jpg)

GRAPHIC (catx-ex99_2s13.jpg)

GRAPHIC (catx-ex99_2s14.jpg)

GRAPHIC (catx-ex99_2s15.jpg)

GRAPHIC (catx-ex99_2s16.jpg)

GRAPHIC (catx-ex99_2s17.jpg)

GRAPHIC (catx-ex99_2s18.jpg)

GRAPHIC (catx-ex99_2s19.jpg)

GRAPHIC (catx-ex99_2s20.jpg)

GRAPHIC (catx-ex99_2s21.jpg)

GRAPHIC (catx-ex99_2s22.jpg)

GRAPHIC (catx-ex99_2s23.jpg)

GRAPHIC (catx-ex99_2s24.jpg)

GRAPHIC (catx-ex99_2s25.jpg)

GRAPHIC (catx-ex99_2s26.jpg)

GRAPHIC (catx-ex99_2s27.jpg)

GRAPHIC (catx-ex99_2s28.jpg)

GRAPHIC (catx-ex99_2s29.jpg)

GRAPHIC (catx-ex99_2s30.jpg)

GRAPHIC (catx-ex99_2s31.jpg)

GRAPHIC (catx-ex99_2s32.jpg)

GRAPHIC (catx-ex99_2s33.jpg)

GRAPHIC (catx-ex99_2s34.jpg)

GRAPHIC (catx-ex99_2s35.jpg)

GRAPHIC (catx-ex99_2s36.jpg)

GRAPHIC (catx-ex99_2s37.jpg)

GRAPHIC (catx-ex99_2s38.jpg)

GRAPHIC (catx-ex99_2s39.jpg)

GRAPHIC (catx-ex99_2s40.jpg)

GRAPHIC (catx-ex99_2s41.jpg)

GRAPHIC (catx-ex99_2s42.jpg)

GRAPHIC (catx-ex99_2s43.jpg)

GRAPHIC (catx-ex99_2s44.jpg)

GRAPHIC (catx-ex99_2s45.jpg)

GRAPHIC (catx-ex99_2s46.jpg)

GRAPHIC (catx-ex99_2s47.jpg)

GRAPHIC (catx-ex99_2s48.jpg)

GRAPHIC (catx-ex99_2s49.jpg)

GRAPHIC (catx-ex99_2s50.jpg)

GRAPHIC (catx-ex99_2s51.jpg)

GRAPHIC (catx-ex99_2s52.jpg)

GRAPHIC (catx-ex99_2s53.jpg)

GRAPHIC (catx-ex99_2s54.jpg)

GRAPHIC (catx-ex99_2s55.jpg)

GRAPHIC (catx-ex99_2s56.jpg)

GRAPHIC (catx-ex99_2s57.jpg)

GRAPHIC (catx-ex99_2s58.jpg)

GRAPHIC (catx-ex99_2s59.jpg)

GRAPHIC (catx-ex99_2s60.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: catx-20260810.htm · Sequence: 1

8-K

0000728387false00007283872026-08-102026-08-10

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 10, 2026

Perspective Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware

001-33407

41-1458152

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

c/o Perspective Therapeutics, Inc.

2401 Elliott Avenue

Suite 320

Seattle, Washington

98121

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (206) 676-0900

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value

CATX

NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 10, 2026, Perspective Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026 and providing recent business highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Form 8-K”) and is incorporated by reference into this Item 2.02.

The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any of the Company’s filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

Item 8.01 Other Events.

Also on August 10, 2026, the Company posted an updated corporate presentation to its website at www.perspectivetherapeutics.com. A copy of the presentation is filed as Exhibit 99.2 to this Form 8-K and is incorporated by reference into this Item 8.01.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1

Press release issued by Perspective Therapeutics, Inc., dated August 10, 2026.

99.2

Corporate presentation.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PERSPECTIVE THERAPEUTICS, INC.

Date:

August 10, 2026

By:

/s/ Joel Sendek

Joel Sendek

Chief Financial Officer

EX-99.1

Filename: catx-ex99_1.htm · Sequence: 2

EX-99.1

Perspective Therapeutics Provides Recent Business Highlights and

Reports 2Q 2026 Results

•

Advancing VMT-α-NET toward a Phase 3 study in neuroendocrine tumors, subject to regulatory alignment: regulatory engagement ongoing; clinical site activation targeted around year-end 2026 subject to regulatory feedback; sufficient isotope access and manufacturing capacity

•

VMT-α-NET study update accepted for oral presentation at ESMO 2026

•

VMT01 melanoma and PSV359 FAP-α clinical programs continue to advance

•

Approximately $237 million in cash, cash equivalents, and short-term investments as of June 30, 2026; expected to be sufficient to fund current planned clinical milestones and operational investments into late 2027

SEATTLE – August 10, 2026 – Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today provided a business update and announced results for the quarter ended June 30, 2026.

“The team at Perspective is highly energized as we continue to build on the significant clinical progress we're making across our pipeline, prepare for our first Phase 3 study, and advance our flagship Chicago manufacturing facility toward completion,” said Thijs Spoor, Perspective's CEO. “As precision oncology continues to evolve, long-term leadership will require differentiated science, integrated manufacturing, and the ability to reliably deliver these therapies at commercial scale. We are continuing to bring the platform that delivers.”

Recent Program Updates

We advanced our four-program 212Pb pipeline, expanded our manufacturing network and attracted strong leadership.

•

Bamzireotide navoxetan (VMT-α-NET) in SSTR2-positive neuroendocrine tumors (NETs) and meningioma: 76 NETs patients across four cohorts and one meningioma patient treated as of July 31. ASCO 2026 interim data were consistent with prior findings and showed continued deepening of response. Updated data on NETs patients will be presented at ESMO on October 23. By late 2026, all 46 Cohort 2 patients will have had the opportunity for at least 60 weeks of follow-up, which is expected to inform the Phase 3 study design.

Preparing for a Phase 3 study evaluating a proposed cumulative 20 mCi (740 MBq) dose administered in up to four treatments every eight weeks. Additional dose cohorts could provide optionality and opportunity to further define VMT-α-NET’s therapeutic window. Phase 3 site activation targeted around year-end 2026, subject to regulatory feedback and protocol finalization.

•

Lapemelanotide zapixetar (VMT01) in MC1R-positive melanoma: 27 patients enrolled across multiple dose cohorts either as monotherapy or in combination with the immune checkpoint inhibitor nivolumab as of July 31. We are focused on a cumulative 9 mCi (333 MBq) dose administered in up to three treatments every eight weeks. Seven patients received this treatment regimen as a monotherapy, and six patients received this dose in combination with nivolumab.

Data presented at ASCO 2026 showed two partial responses among seven patients treated with 3.0 mCi monotherapy; safety data from 27 patients showed treatment was generally well tolerated. Six nivolumab combination patients are expected to reach at least 24 weeks of follow-up by late 2026.

•

PSV359 in FAP-α-positive solid tumors: 17 patients treated across three dose cohorts as of July 31. Cohort 3 opened and closed during 2Q 2026. The next clinical update is planned in 2027.

•

PSV594 in CCK2R-positive solid tumors: Preclinical data and first-in-human biodistribution observations support continued pre-IND development of PSV594.

Manufacturing: We expect the Chicago metro site to complete construction in early 2027, followed by the Los Angeles metro site in 2H 2027, expanding the network to four regional sites by the end of 2027. We believe we have sufficient capacity and isotope access to support ongoing studies and the planned VMT-α-NET Phase 3 study.

Corporate update: In July 2026, we announced that Paul Lyne, Ph.D. was appointed as Chief Science Officer.

Second Quarter 2026 Financial Summary

Cash, cash equivalents, and short-term investments as of June 30, 2026, were approximately $237 million as compared to approximately $145 million as of December 31, 2025. We believe our cash, cash equivalents, and short-term investments are sufficient to fund our current planned clinical milestones and operational investments into late 2027.

•

Research and development expenses were $21.5 million for the three months ended June 30, 2026, compared to $16.6 million for the three months ended June 30, 2025.

•

General and administrative expenses were $7.8 million for the three months ended June 30, 2026, compared to $7.7 million for the three months ended June 30, 2025.

•

Net loss for the three months ended June 30, 2026, was $26.8 million, or $0.22 per basic and diluted share, compared to a net loss of $21.5 million, or $0.29 per basic and diluted share, for the same period in 2025.

About Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-generating isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging techniques that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables visualization of the specific tumor and subsequent treatment, potentially improving efficacy and minimizing toxicity.

The Company is advancing a portfolio of clinical-stage programs in the U.S., including VMT-α-NET (neuroendocrine tumors), VMT01 (melanoma), and PSV359 (solid tumors).

The Company is expanding its regional finished drug product candidate supply network, enabled by its proprietary 224Ra/212Pb generator platform used to manufacture clinical drug product candidates, to support the delivery of patient-ready drug product candidates for clinical trials and, if approved, commercial operations.

For more information, please visit the Company's website at www.perspectivetherapeutics.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential," or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include express or implied statements concerning, among other things, the Company's expectations regarding cash runway; the Company’s manufacturing, distribution and commercialization plans and capabilities; the Company’s clinical and preclinical development plans and the expected timing for the release of additional data from its development programs; the Company’s beliefs that it has sufficient isotope access to support ongoing clinical studies; the Company’s beliefs that its product candidates address certain unmet medical needs; the Company’s expectations regarding regulatory pathways for its product candidates, the Company’s interactions with regulatory agencies and the expected timing thereof; and other statements that are not historical fact.

The Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Known risk factors include that the Company’s preclinical development plans and clinical trials may be more costly or take longer to complete than anticipated, or may never be completed, or may not generate results that warrant future development of the tested product candidate; the Company may elect to change its strategy regarding its product candidates and development activities; our ability to obtain isotopes pursuant to our supply agreement with the U.S. Department of Energy; economic and market conditions may worsen; regulatory agencies may issue decisions that negatively impact the Company’s product candidates and clinical development plans; and risks related to the sufficiency of the Company’s cash resources for its future operating expenses and capital expenditures. A more complete discussion of the risks and uncertainties facing the Company appears under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Media and Investor Relations Contact:

Perspective Therapeutics IR:

Annie J. Cheng, CFA

ir@perspectivetherapeutics.com

ENTENTE Network of Companies

Virginia Amann

virginiaamann@ententeinc.com

Perspective Therapeutics, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(In thousands, except shares and par value data)

June 30,

December 31,

2026

2025

(unaudited)

ASSETS

Current assets:

Cash and cash equivalents

48,488

30,629

Short-term investments

188,388

114,108

Accounts receivable, net of allowance for doubtful accounts: $375 for each period

269

Prepaid expenses and other current assets

4,378

3,646

Total current assets

241,523

148,389

Noncurrent assets:

Property and equipment, net

107,797

76,597

Right of use asset

2,196

1,500

Intangible assets, in-process research and development

40,000

Other assets

509

486

Total assets

392,025

266,972

LIABILITIES AND STOCKHOLDERSʼ EQUITY

Current liabilities:

Accounts payable and accrued expenses

29,418

20,511

Lease liability

1,097

623

Accrued personnel expenses

5,972

7,489

Note payable

Total current liabilities

36,544

28,679

Noncurrent liabilities:

Lease liability, net of current portion

1,269

1,005

Note payable, net of current portion

1,540

1,569

Deferred income

26,600

Deferred tax liability

1,702

Other noncurrent liabilities

507

386

Total liabilities

68,162

59,941

Stockholdersʼ equity:

Preferred stock: $0.001 par value; 7,000,000 shares authorized; 5,000,000

designated Series B convertible; no shares issued

Common stock: $0.001 par value; 750,000,000 shares authorized; 114,086,092

and 74,337,990 shares issued

114

Additional paid-in capital

711,785

541,687

Accumulated other comprehensive (loss) income

(221

)

110

Accumulated deficit

(387,815

)

(334,840

)

Total stockholdersʼ equity

323,863

207,031

Total liabilities and stockholdersʼ equity

392,025

266,972

Perspective Therapeutics, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)

(Dollars and shares in thousands, except for per-share amounts)

Three Months Ended June 30,

Six Months Ended June 30,

2026

2025

2026

2025

Grant revenue

290

157

632

Operating expenses:

Research and development

21,544

16,620

42,916

30,952

General and administrative

7,795

7,709

14,780

15,551

Total operating expenses

29,339

24,329

57,696

46,503

Operating loss

(29,258

)

(24,039

)

(57,539

)

(45,871

)

Non-operating income (expense):

Interest income

2,347

2,159

4,544

4,543

Interest and other expense

(71

)

(119

)

(176

)

(247

)

Other income from a related party

1,400

Equity in loss of affiliate

)

Total non-operating income, net

2,275

2,040

4,367

5,695

Net loss from continuing operations

(26,983

)

(21,999

)

(53,172

)

(40,176

)

Net gain from discontinued operations

197

514

197

514

Net loss before income taxes

(26,786

)

(21,485

)

(52,975

)

(39,662

)

Deferred income tax benefit

Net loss

(26,786

)

(21,485

)

(52,975

)

(39,662

)

Basic and diluted loss per share:

Loss from continuing operations

(0.22

)

(0.30

)

(0.47

)

(0.55

)

Gain from discontinued operations

0.01

Basic and diluted loss per share

(0.22

)

(0.29

)

(0.47

)

(0.54

)

Weighted average shares used in

computing net loss per share:

Basic and diluted

120,651

74,235

112,174

73,301

Unrealized gain (loss) on available-

for-sale securities

(16

)

(331

)

Comprehensive loss

(26,781

)

(21,501

)

(53,306

)

(39,608

)

EX-99.2

Filename: catx-ex99_2.htm · Sequence: 3

Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals

Engineering the Alpha Advantage in Targeted Oncology

Unlocking New Treatment Options Across Solid Tumors:

Optimizing the Entire System

Rapidly Advancing Best-in-Class Next Generation Radiopharmaceuticals

Optimizing Structural Chemistry:

Choosing the Right Isotope

Not All ²¹²Pb Programs Are Created Equal

Advancing a Theranostic Approach:

Solid Tumors are an Attractive Market for Radiopharmaceuticals

Expanding the Addressable Market

Direct-to-Hospital Delivery through Integrated Isotope Production

Daily Production at Regional Sites Ensures Supply of Ready-to-Administer Product

Reaching the Largest Addressable Market with Regional Manufacturing

Advancing a Diverse 212Pb-Based Oncology Portfolio

SSTR2+ Neuroendocrine Tumors is a Large, Growing Market with Significant Unmet Need

VMT-α-NET: Potential First-in-Class 212Pb-Radioligand Therapy Targeting SSTR2

Ongoing Phase 1/2a to Establish Broad Therapeutic Window for VMT-α-NET

VMT-⍺-NET: Baseline Patient Characteristics in ASCO 2026 Data Analysis

Patient Exposure and Follow-up with [212Pb]VMT-α-NET in ASCO 2026 Data Analysis

VMT-α-NET Best Response Deepens Over Time

VMT-α-NET Responses Deepen Over Time

VMT-⍺-NET: Durable Disease Control Across All Doses

Spider Plot of Tumor Change Over Time by Patient

Best-in-class Safety Profile1

Blood Creatinine During Follow-up for All Patients Treated (n=68)

VMT-α-NET ’s Compelling Profile Supports Potential Registration Study at Current Dose Level

Checkpoint Inhibitors Transformed Care of Melanoma but Leave Many Patients Behind

VMT01: Potential First-in-Class 212Pb Therapy Targeting MC1R for Melanoma

Ongoing Phase 1/2a Open-Label Trial For VMT01 in Melanoma

Preliminary Anti-tumor Activity Observed at 3.0 mCi Dose of VMT01

Treatment Emergent Adverse Events (All Grades, Occurring in ≥ 10% of Patients)

VMT01 Clinical Data Support Further Development

FAP-ɑ is an Attractive Cancer Target with Broad Solid Tumor Potential

PSV359: Potential First-in-Class 212Pb Therapy Targeting FAP-ɑ for Solid Tumors

Ongoing Open-label Phase 1/2a Trial For PSV359 in Advanced Solid Tumors

PSV359 has Improved Tumor Retention, Highlighting its Potential as a Therapeutic Agent

Strong IP Portfolio Covering All Aspects of Radiopharmaceutical Value Chain

A Decade of Deliberate, End-to-End Engineering

Built Over a Decade:

Abbreviations

APPENDIX

Deep Leadership Across Radiopharmaceutical and Drug Development

NETs Trials

Patient with Confirmed PR After [212Pb]VMT-α-NET Treatment

Refractory Metastatic Melanoma Trials

ICI Combo Rationale: Strong Synergy with VMT01 in Melanoma

Metastatic Melanoma: Confirmed Partial Response after 2 Cycles of [212Pb]VMT01

Perspective’s CCK2R81 in Medullary Thyroid Cancer Compared to FDG and Fluorodopa

Construct Designed for Better Clinical Outcome

212Pb Uniquely Suited for Combination with Immune Checkpoint Inhibitors

Kinetics Matter: 212Pb Hits Hard and Fast for Strong Activity with Less Systemic Exposure

GRAPHIC

Filename: img236230851_0.jpg · Sequence: 4

Binary file (41935 bytes)

Download img236230851_0.jpg

GRAPHIC

Filename: catx-ex99_2s1.jpg · Sequence: 5

Binary file (158284 bytes)

Download catx-ex99_2s1.jpg

GRAPHIC

Filename: catx-ex99_2s2.jpg · Sequence: 6

Binary file (536297 bytes)

Download catx-ex99_2s2.jpg

GRAPHIC

Filename: catx-ex99_2s3.jpg · Sequence: 7

Binary file (276763 bytes)

Download catx-ex99_2s3.jpg

GRAPHIC

Filename: catx-ex99_2s4.jpg · Sequence: 8

Binary file (222440 bytes)

Download catx-ex99_2s4.jpg

GRAPHIC

Filename: catx-ex99_2s5.jpg · Sequence: 9

Binary file (275005 bytes)

Download catx-ex99_2s5.jpg

GRAPHIC

Filename: catx-ex99_2s6.jpg · Sequence: 10

Binary file (287937 bytes)

Download catx-ex99_2s6.jpg

GRAPHIC

Filename: catx-ex99_2s7.jpg · Sequence: 11

Binary file (253018 bytes)

Download catx-ex99_2s7.jpg

GRAPHIC

Filename: catx-ex99_2s8.jpg · Sequence: 12

Binary file (240418 bytes)

Download catx-ex99_2s8.jpg

GRAPHIC

Filename: catx-ex99_2s9.jpg · Sequence: 13

Binary file (269643 bytes)

Download catx-ex99_2s9.jpg

GRAPHIC

Filename: catx-ex99_2s10.jpg · Sequence: 14

Binary file (273025 bytes)

Download catx-ex99_2s10.jpg

GRAPHIC

Filename: catx-ex99_2s11.jpg · Sequence: 15

Binary file (209755 bytes)

Download catx-ex99_2s11.jpg

GRAPHIC

Filename: catx-ex99_2s12.jpg · Sequence: 16

Binary file (229130 bytes)

Download catx-ex99_2s12.jpg

GRAPHIC

Filename: catx-ex99_2s13.jpg · Sequence: 17

Binary file (291990 bytes)

Download catx-ex99_2s13.jpg

GRAPHIC

Filename: catx-ex99_2s14.jpg · Sequence: 18

Binary file (223483 bytes)

Download catx-ex99_2s14.jpg

GRAPHIC

Filename: catx-ex99_2s15.jpg · Sequence: 19

Binary file (274179 bytes)

Download catx-ex99_2s15.jpg

GRAPHIC

Filename: catx-ex99_2s16.jpg · Sequence: 20

Binary file (385932 bytes)

Download catx-ex99_2s16.jpg

GRAPHIC

Filename: catx-ex99_2s17.jpg · Sequence: 21

Binary file (252529 bytes)

Download catx-ex99_2s17.jpg

GRAPHIC

Filename: catx-ex99_2s18.jpg · Sequence: 22

Binary file (292962 bytes)

Download catx-ex99_2s18.jpg

GRAPHIC

Filename: catx-ex99_2s19.jpg · Sequence: 23

Binary file (241743 bytes)

Download catx-ex99_2s19.jpg

GRAPHIC

Filename: catx-ex99_2s20.jpg · Sequence: 24

Binary file (252700 bytes)

Download catx-ex99_2s20.jpg

GRAPHIC

Filename: catx-ex99_2s21.jpg · Sequence: 25

Binary file (292565 bytes)

Download catx-ex99_2s21.jpg

GRAPHIC

Filename: catx-ex99_2s22.jpg · Sequence: 26

Binary file (235715 bytes)

Download catx-ex99_2s22.jpg

GRAPHIC

Filename: catx-ex99_2s23.jpg · Sequence: 27

Binary file (226115 bytes)

Download catx-ex99_2s23.jpg

GRAPHIC

Filename: catx-ex99_2s24.jpg · Sequence: 28

Binary file (233534 bytes)

Download catx-ex99_2s24.jpg

GRAPHIC

Filename: catx-ex99_2s25.jpg · Sequence: 29

Binary file (267326 bytes)

Download catx-ex99_2s25.jpg

GRAPHIC

Filename: catx-ex99_2s26.jpg · Sequence: 30

Binary file (257699 bytes)

Download catx-ex99_2s26.jpg

GRAPHIC

Filename: catx-ex99_2s27.jpg · Sequence: 31

Binary file (247547 bytes)

Download catx-ex99_2s27.jpg

GRAPHIC

Filename: catx-ex99_2s28.jpg · Sequence: 32

Binary file (209203 bytes)

Download catx-ex99_2s28.jpg

GRAPHIC

Filename: catx-ex99_2s29.jpg · Sequence: 33

Binary file (262717 bytes)

Download catx-ex99_2s29.jpg

GRAPHIC

Filename: catx-ex99_2s30.jpg · Sequence: 34

Binary file (263985 bytes)

Download catx-ex99_2s30.jpg

GRAPHIC

Filename: catx-ex99_2s31.jpg · Sequence: 35

Binary file (255731 bytes)

Download catx-ex99_2s31.jpg

GRAPHIC

Filename: catx-ex99_2s32.jpg · Sequence: 36

Binary file (221898 bytes)

Download catx-ex99_2s32.jpg

GRAPHIC

Filename: catx-ex99_2s33.jpg · Sequence: 37

Binary file (262325 bytes)

Download catx-ex99_2s33.jpg

GRAPHIC

Filename: catx-ex99_2s34.jpg · Sequence: 38

Binary file (228842 bytes)

Download catx-ex99_2s34.jpg

GRAPHIC

Filename: catx-ex99_2s35.jpg · Sequence: 39

Binary file (242356 bytes)

Download catx-ex99_2s35.jpg

GRAPHIC

Filename: catx-ex99_2s36.jpg · Sequence: 40

Binary file (258185 bytes)

Download catx-ex99_2s36.jpg

GRAPHIC

Filename: catx-ex99_2s37.jpg · Sequence: 41

Binary file (255209 bytes)

Download catx-ex99_2s37.jpg

GRAPHIC

Filename: catx-ex99_2s38.jpg · Sequence: 42

Binary file (203897 bytes)

Download catx-ex99_2s38.jpg

GRAPHIC

Filename: catx-ex99_2s39.jpg · Sequence: 43

Binary file (208377 bytes)

Download catx-ex99_2s39.jpg

GRAPHIC

Filename: catx-ex99_2s40.jpg · Sequence: 44

Binary file (166923 bytes)

Download catx-ex99_2s40.jpg

GRAPHIC

Filename: catx-ex99_2s41.jpg · Sequence: 45

Binary file (189106 bytes)

Download catx-ex99_2s41.jpg

GRAPHIC

Filename: catx-ex99_2s42.jpg · Sequence: 46

Binary file (276729 bytes)

Download catx-ex99_2s42.jpg

GRAPHIC

Filename: catx-ex99_2s43.jpg · Sequence: 47

Binary file (191990 bytes)

Download catx-ex99_2s43.jpg

GRAPHIC

Filename: catx-ex99_2s44.jpg · Sequence: 48

Binary file (99210 bytes)

Download catx-ex99_2s44.jpg

GRAPHIC

Filename: catx-ex99_2s45.jpg · Sequence: 49

Binary file (274206 bytes)

Download catx-ex99_2s45.jpg

GRAPHIC

Filename: catx-ex99_2s46.jpg · Sequence: 50

Binary file (86547 bytes)

Download catx-ex99_2s46.jpg

GRAPHIC

Filename: catx-ex99_2s47.jpg · Sequence: 51

Binary file (298973 bytes)

Download catx-ex99_2s47.jpg

GRAPHIC

Filename: catx-ex99_2s48.jpg · Sequence: 52

Binary file (343372 bytes)

Download catx-ex99_2s48.jpg

GRAPHIC

Filename: catx-ex99_2s49.jpg · Sequence: 53

Binary file (267679 bytes)

Download catx-ex99_2s49.jpg

GRAPHIC

Filename: catx-ex99_2s50.jpg · Sequence: 54

Binary file (304470 bytes)

Download catx-ex99_2s50.jpg

GRAPHIC

Filename: catx-ex99_2s51.jpg · Sequence: 55

Binary file (306101 bytes)

Download catx-ex99_2s51.jpg

GRAPHIC

Filename: catx-ex99_2s52.jpg · Sequence: 56

Binary file (177480 bytes)

Download catx-ex99_2s52.jpg

GRAPHIC

Filename: catx-ex99_2s53.jpg · Sequence: 57

Binary file (271020 bytes)

Download catx-ex99_2s53.jpg

GRAPHIC

Filename: catx-ex99_2s54.jpg · Sequence: 58

Binary file (252193 bytes)

Download catx-ex99_2s54.jpg

GRAPHIC

Filename: catx-ex99_2s55.jpg · Sequence: 59

Binary file (224826 bytes)

Download catx-ex99_2s55.jpg

GRAPHIC

Filename: catx-ex99_2s56.jpg · Sequence: 60

Binary file (301454 bytes)

Download catx-ex99_2s56.jpg

GRAPHIC

Filename: catx-ex99_2s57.jpg · Sequence: 61

Binary file (285043 bytes)

Download catx-ex99_2s57.jpg

GRAPHIC

Filename: catx-ex99_2s58.jpg · Sequence: 62

Binary file (190783 bytes)

Download catx-ex99_2s58.jpg

GRAPHIC

Filename: catx-ex99_2s59.jpg · Sequence: 63

Binary file (231617 bytes)

Download catx-ex99_2s59.jpg

GRAPHIC

Filename: catx-ex99_2s60.jpg · Sequence: 64

Binary file (327515 bytes)

Download catx-ex99_2s60.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 67

v3.26.1

Document And Entity Information

Aug. 10, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 10, 2026

Entity Registrant Name

Perspective Therapeutics, Inc.

Entity Central Index Key

0000728387

Entity Emerging Growth Company

false

Entity File Number

001-33407

Entity Incorporation, State or Country Code

Entity Tax Identification Number

41-1458152

Entity Address, Address Line One

c/o Perspective Therapeutics, Inc.

Entity Address, Address Line Two

2401 Elliott Avenue

Entity Address, Address Line Three

Suite 320

Entity Address, City or Town

Seattle

Entity Address, State or Province

Entity Address, Postal Zip Code

98121

City Area Code

(206)

Local Phone Number

676-0900

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, $0.001 par value

Trading Symbol

CATX

Security Exchange Name

NYSEAMER

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 3 such as an Office Park

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine3

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration